RE:Does Bioasis have a responsibility to update Shareholders?The company is presumably in intense multi-party negotiations towards some kind of resolution. Forcing it to cough up information in this time period to those it is negotiating against could be like handcuffing it. Negotiations can be difficult to fully understand in the best of times given the posturing until a deal is signed.
Potentially without a data package for its lead xB3 program as Hunter data was expected in Q2 2023 and is potentially years from clinical trials it will be interesting to see what happens as BTI attemps to address immediate material debt and create a cash runway to material events. Hunter itself is years behind Denali's Hunter program which is in trials with a big lead-to-market. Focus would appear on BTI's new EGF assets which appear to have visibility to clinical trials as they are said Phase II ready.
The Biodexa plan sure had a lot more appeal than the visibility in the current situation.
How about a $10 million financing at $.025 with a full warrant with an acceleration clause for 800 million 800 million new shares?